|(what is this?)|
Mecasermin (INN, trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.
This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.
- Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
- "Increlex". Drugs.com. Retrieved 10 January 2010.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|